238 related articles for article (PubMed ID: 28133974)
1. Novel therapeutic approaches in chondrosarcoma.
Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
[TBL] [Abstract][Full Text] [Related]
2. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
3. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
Zhang YX; van Oosterwijk JG; Sicinska E; Moss S; Remillard SP; van Wezel T; Bühnemann C; Hassan AB; Demetri GD; Bovée JV; Wagner AJ
Clin Cancer Res; 2013 Jul; 19(14):3796-807. PubMed ID: 23714727
[TBL] [Abstract][Full Text] [Related]
4. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
5. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV
Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
7. Biological aspects of chondrosarcoma: Leaps and hurdles.
Mery B; Espenel S; Guy JB; Rancoule C; Vallard A; Aloy MT; Rodriguez-Lafrasse C; Magné N
Crit Rev Oncol Hematol; 2018 Jun; 126():32-36. PubMed ID: 29759564
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
11. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
13. Targeting PI3K Signaling in Combination Cancer Therapy.
Pons-Tostivint E; Thibault B; Guillermet-Guibert J
Trends Cancer; 2017 Jun; 3(6):454-469. PubMed ID: 28718419
[TBL] [Abstract][Full Text] [Related]
14. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
15. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Schrage YM; Briaire-de Bruijn IH; de Miranda NF; van Oosterwijk J; Taminiau AH; van Wezel T; Hogendoorn PC; Bovée JV
Cancer Res; 2009 Aug; 69(15):6216-22. PubMed ID: 19602594
[TBL] [Abstract][Full Text] [Related]
16. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
17. A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.
de Melo AC; Paulino E; Garces ÁH
Oxid Med Cell Longev; 2017; 2017():4809751. PubMed ID: 28286604
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
19. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
20. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
